Ashton Thomas Private Wealth LLC Purchases 3,633 Shares of AbbVie Inc. $ABBV

Ashton Thomas Private Wealth LLC boosted its position in AbbVie Inc. (NYSE:ABBV) by 8.9% during the third quarter, Holdings Channel.com reports. The fund owned 44,577 shares of the company’s stock after acquiring an additional 3,633 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in AbbVie were worth $10,321,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Evolution Wealth Management Inc. purchased a new position in AbbVie during the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth approximately $36,000. Delos Wealth Advisors LLC purchased a new stake in shares of AbbVie in the 2nd quarter worth approximately $39,000. Finally, Bear Mountain Capital Inc. increased its position in AbbVie by 480.6% during the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock valued at $40,000 after buying an additional 173 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on ABBV shares. Citigroup decreased their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. UBS Group reissued a “neutral” rating on shares of AbbVie in a report on Tuesday, January 13th. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. Scotiabank began coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target for the company. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a research note on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $251.17.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Regulatory progress: AbbVie submitted applications to the FDA and EMA seeking approval for upadacitinib (RINVOQ) in adults and adolescents with vitiligo after positive Phase 3 Viti‑Up results. Approval would create the first systemic treatment option for vitiligo and materially expand RINVOQ’s addressable market. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Adults and Adolescents With Vitiligo
• Positive Sentiment: Post‑Humira growth roadmap: Management is emphasizing growth from RINVOQ label expansion and cell therapy investments to replace declining Humira sales — a strategic narrative investors view as critical to sustaining revenue and EPS over the medium term. AbbVie Targets Post Humira Growth With Cell Therapy And RINVOQ Expansion
• Positive Sentiment: Analyst tone ahead of Q4 is constructive: Several previews and analyst notes expect a return to profit and cite Skyrizi/RINVOQ strength, prompting some buy recommendations ahead of earnings. Positive analyst positioning can support the stock into the report. Buy AbbVie Stock Before Q4 Earnings? Here’s What to Know
• Positive Sentiment: Market narratives remain bullish on long-term upside and dividend quality after AbbVie navigated the Humira patent cliff — supporting investor confidence in total returns. 2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
• Neutral Sentiment: Earnings preview/expectations: Multiple previews (Seeking Alpha, MarketWatch, Yahoo) expect revenue growth and a Q4 swing to profit — the print and management commentary will be the immediate catalyst for volatility. AbbVie Q4 Preview: Here’s what to expect
• Neutral Sentiment: Marketing/business updates are ongoing but lower impact: Allergan Aesthetics and migraine education campaigns support brand and aesthetics business engagement, but are unlikely to move near‑term revenue materially. Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
• Negative Sentiment: Relative performance concerns: Data show AbbVie underperformed some peers despite intraday gains, a signal that investors are weighing competitive dynamics and pipeline execution versus peers. Short‑term flows could pressure the stock if the upcoming print disappoints. AbbVie Inc. stock underperforms Monday when compared to competitors despite daily gains
• Negative Sentiment: Policy and pricing risk: Coverage on a large drug‑pricing pact and broader policy shifts highlights ongoing pricing/regulatory risks that could weigh on long‑term margins if unfavorable terms or reimbursement pressures intensify. Monitor policy developments closely. AbbVie’s US$100b Drug Pricing Pact Reshapes Growth And Policy Outlook

AbbVie Stock Performance

ABBV opened at $225.53 on Wednesday. The stock has a market capitalization of $398.60 billion, a price-to-earnings ratio of 170.86, a PEG ratio of 0.93 and a beta of 0.35. The company has a fifty day moving average of $224.20 and a 200 day moving average of $219.16. AbbVie Inc. has a fifty-two week low of $164.39 and a fifty-two week high of $244.81.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.